Key result
Catheter ablation demonstrated long-term efficacy with a 94% arrhythmic event-free survival compared to 45% in ICD carriers among high-risk patients with Brugada syndrome.
Why the study?
Does catheter ablation improve arrhythmic event-free survival compared to ICD therapy in high-risk patients with Brugada syndrome?
Does catheter ablation improve arrhythmic event-free survival compared to ICD therapy in high-risk patients with Brugada syndrome?
Answers are grounded in this paper and cite their sources.
Catheter ablation is a promising and efficacious alternative to ICD therapy in high-risk symptomatic patients with Brugada syndrome.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Conte et al. (2023) conducted an editorial in Brugada syndrome (n=40). Catheter ablation vs. Implantable cardioverter-defibrillator (ICD) was evaluated on Arrhythmic event-free survival. Catheter ablation demonstrated long-term efficacy with a 94% arrhythmic event-free survival compared to 45% in ICD carriers among high-risk patients with Brugada syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: